– Investor Day
Neurogene Reports First Patient Dosed In High-Dose Cohort Of NGN-401 Gene Therapy Clinical Trial For Rett Syndrome
High-dose NGN-401 has been well-tolerated, and low-dose NGN-401 continues to show a favorable safety profileInterim safety data presented at the International Rett Syndrome Foundation (IRSF) ASCEND SummitNeurogene Inc.